Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flow from operating activities
Net (loss) income	$ (11,330)	$ 124,044
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Stock-based compensation expense	3,573	2,558
Depreciation	1,196	1,075
Amortization of premiums and discounts on marketable securities	(1,931)	(17)
Loss on disposal of fixed assets	59	44
Changes in operating assets and liabilities:
Accounts receivable	79,313	(25,000)
Related party collaboration receivable	721	(71)
Prepaid expenses and other current assets	(794)	1,411
Operating lease, right-of-use asset	1,057	469
Other non-current assets	(15)
Accounts payable	5,975	1,132
Accrued expenses	(9,305)	(122)
Operating lease liabilities	891	(683)
Deferred revenue	(10,643)	18,725
Net cash provided by operating activities	58,767	123,565
Cash flow from investing activities
Purchases of property and equipment	(2,141)	(509)
Purchases of marketable securities	(203,852)
Proceeds from sales and maturities of marketable securities	109,928	15,000
Net cash (used in) provided by investing activities	(96,065)	14,491
Cash flow from financing activities
Proceeds from the exercise of stock options	78	185
Proceeds from the issuance of common stock in connection with the underwritten public offering	93,473
Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement	19,305
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement		31,121
Net cash provided by financing activities	112,856	31,306
Net increase in cash, cash equivalents, and restricted cash	75,558	169,362
Cash, cash equivalents, and restricted cash, beginning of period	70,395	100,474
Cash, cash equivalents, and restricted cash, end of period	145,953	269,836
Supplemental disclosure of cash and non-cash activities
Capital expenditures incurred but not yet paid		$ 109
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$ 26,751